Invivyd unveils VMS063 candidate at IDWeek for measles therapy
Invivyd announced the presentation of VMS063, a monoclonal antibody candidate aimed at the treatment and prevention of measles, at IDWeek 2026. The potential best-in-class candidate demonstrates ...